Assisted reproductive technology market to exceed $440 million by 2030

Improvements in Assisted Reproductive Technology (ART) have enabled millions of across world facing infertility to conceive over past few decades, and this trend is likely to continue well into future

IANS New Delhi
Photo: Bloomberg

Photo: Bloomberg

Listen to This Article

Improvements in Assisted Reproductive Technology (ART) have enabled millions of women across the world facing infertility to conceive over the past few decades, and this trend is likely to continue well into the future, boosting the value of the consumable ART devices market to exceed $440 million by 2030, according to a report on Wednesday.

ART collectively refers to reproductive health techniques, procedures, and devices that help infertile women achieve pregnancy. For decades now, several techniques of ART have been in use with varying pregnancy success rates, but the most performed one now is called in vitro fertilisation (IVF).

A procedure of IVF is typically referred to as a cycle, as it usually takes approximately two weeks to complete the standard fresh IVF cycle given the number of time-sensitive steps involved.

According to the latest market model by data and analytics company GlobalData, the consumable ART devices market is set to grow at a compound annual growth rate of 6 per cent through 2030.

"Some of the key drivers of global market growth in IVF device sales are the increasing number of fertility clinics, an increase in the average age of couples choosing to have children, and an increasing number of women opting to undergo IVF as it has proven to improve pregnancy success rates," said Brian Hicks, Senior Analyst at GlobalData, in a statement.

Devices used in ART cycles vary widely depending on the specific techniques used and the manufacturers from which fertility clinics opt to purchase them. Broadly, ART devices are categorised as installed-base systems or consumable devices.

Also Read

Fertility chain Indira IVF seeks partnerships to expand clinics in India

Mankind Pharma IPO to open next week: Check price band, GMP, other details

Indira IVF to invest Rs 60 cr for diagnostics foray over next 5 years

Mankind Pharma IPO opens today: Check GMP, price band, other details here

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

Auto parts firm Pricol moves CCI over Minda plan to buy 24.5% stake

Peak power demand hits historic high of 220 Gw, may cross that level soon

Chemistry of producing pure hydrogen from non-fossil fuels revealed

Poor DPRs by companies causing project delays, accidents: Nitin Gadkari

Indian hospitality sector on a comeback trail with promising growth-report

Examples of system devices include incubators and biological safety cabinets, where their lifespans exceed several years with proper maintenance.

Consumables, on the other hand, include single use, disposable devices like catheters and pipettes, which need to be repurchased for every new step of a procedure and for every patient.

"Emerging technologies will also play a role in drawing more patients, such as time-lapse embryo culture and the integration of artificial intelligence (AI), whereby patient profiles and embryo development are quantitatively assessed to improve pregnancy success rates using the healthiest embryos," Hicks said.

"The increased awareness and access to ART, in turn, has driven the market growth for consumable ART devices like oocyte aspiration needles, IVF media, and embryo transfer catheters," he said.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: May 17 2023 | 9:20 PM IST

Explore News